Johnson & Johnson $JNJ Shares Bought by Algert Global LLC

Algert Global LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 30.2% in the 1st quarter, Holdings Channel.com reports. The fund owned 32,607 shares of the company’s stock after buying an additional 7,561 shares during the quarter. Algert Global LLC’s holdings in Johnson & Johnson were worth $5,408,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its stake in shares of Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after buying an additional 6,332 shares in the last quarter. Hudson Value Partners LLC grew its stake in shares of Johnson & Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company’s stock valued at $5,648,000 after buying an additional 1,022 shares in the last quarter. Mirabella Financial Services LLP acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $955,000. Kayne Anderson Rudnick Investment Management LLC grew its stake in shares of Johnson & Johnson by 9.2% in the fourth quarter. Kayne Anderson Rudnick Investment Management LLC now owns 118,700 shares of the company’s stock valued at $17,166,000 after buying an additional 9,977 shares in the last quarter. Finally, Transce3nd LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at $163,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

JNJ stock opened at $176.26 on Tuesday. The business has a 50 day moving average price of $161.70 and a 200 day moving average price of $158.60. The stock has a market cap of $424.49 billion, a price-to-earnings ratio of 18.85, a PEG ratio of 2.25 and a beta of 0.41. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $177.57. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the previous year, the business earned $2.82 EPS. The business’s quarterly revenue was up 5.8% on a year-over-year basis. Equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 3.0%. The ex-dividend date of this dividend is Tuesday, August 26th. Johnson & Johnson’s payout ratio is presently 55.61%.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Benchmark raised Johnson & Johnson to a “strong-buy” rating in a research note on Thursday, April 24th. Erste Group Bank upgraded Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Wednesday, July 23rd. Bank of America lifted their target price on Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a report on Thursday, July 17th. Leerink Partners lowered Johnson & Johnson from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $169.00 to $153.00 in a report on Tuesday, May 13th. Finally, UBS Group lifted their target price on Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a report on Thursday, July 17th. Nine investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.